We help leading organizations provide effective non-drug programs for mental health support
With our digital programs, employers and health plans can lower health care costs, deliver meaningful outcomes, and encourage healthier lifestyles.
It’s no secret:
Mental health conditions are common, costly, and have far-reaching consequences
18-36%
of people experience a mental health condition in their lifetime.1
300%+
When people don’t have access to mental health support, their employers can spend up to 300% more on health care costs.2
55%
of adults with a mental health condition do not get adequate support.3
Trusted by the world’s leading organizations
For nearly a decade, we’ve been empowering employers and health plans to help millions live well with their mental health conditions.
Simple to adopt,
low-lift engagement
The medication assessment program from Big Health is the easiest way to offer non-drug options to members of your population in need.
Add coverage to your
pharmacy plan
Pre-approved by major pharmacy benefit managers, add coverage in as few as 10 days.
Offer access via
existing care pathways
Easily reach members when they need it.
Bill via pharmacy invoice
Deep integrations mean you get to bill via your pharmacy invoice.
Mental health programs with proven outcomes and cost savings
Outcomes reporting
Receive data on improvements in mental wellbeing including sleep, anxiety, stress, and mood.
Near-term ROI
Sleepio has been shown to impact health care spending with cost-effectiveness increasing over time.4
High engagement
Reach 30-40% of your population within the first year with optional custom communication support.
Custom population engagement strategies,
white-glove customer experience
For the past decade, we’ve been helping large organizations tackle mental health stigma and access barriers with custom-built engagement strategies. From nurses to truck drivers to members working from home or abroad, we’ve got you covered.
Supporting practicing clinicians
Partner with us to provide your patients with accessible, non-drug programs for their mental health conditions.
You might also enjoy…
Private: Is mental health care truly equitable?
To shed light on how to reduce inequities in mental health care, Big Health’s CEO and Co-founder Peter Hames moderated…
Three lessons from the biggest companies on their approach to mental health
Our benchmark report shows how 35+ of the most innovative companies — representing 2.5 million employees lives — are supporting…
Integrate digital therapeutics into the pharmacy pathway
Effective mental health care via your PBM, faster and easier than ever.
During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.
Spark Direct is a digital program that may help individuals live well with major depressive disorder (MDD) and symptoms of depression by providing them with cognitive and behavioral techniques that can improve mood. Spark Direct has not been reviewed or approved by the Food & Drug Administration and is not intended to diagnose or treat any medical condition. Please read the instructions for use.
1. Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Chatterji, S., Lee, S., Ormel, J., … & Wang, P. S. (2009). The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiology and Psychiatric Sciences, 18(1), 23-33.
2. Trzcinski, A. (2021, March 15). Forrester. Retrieved from: https://www.forrester.com/report/Invest+Now+Build+A+Resilient+Workforce+By+Prioritizing+Employee+Mental+Health/RES164922.
3. Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/.
4. Darden, M., Espie, C. A., Carl, J. R., Henry, A. L., Kanady, J. C., Krystal, A. D., & Miller, C. B. (2021). Cost-effectiveness of digital cognitive behavioral therapy (Sleepio) for insomnia: a Markov simulation model in the United States. Sleep, 44(4).
DOC-3045 Effective 11/2023
